Cargando…

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report

INTRODUCTION: The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment with an EGFR tyrosine kinase inhibitor (TKI) have received extensive investigations. The phenotypic transformation to s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kok, Victor C., Lee, Chien-Kuan, Chiang, Yu-Hsin, Wang, Ming-Chih, Lu, Yen-Te, Cherng, Chiu-Chun, Lee, Pei-Yu, Wang, Ke-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012892/ https://www.ncbi.nlm.nih.gov/pubmed/33816221 http://dx.doi.org/10.3389/fonc.2021.564799

Ejemplares similares

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Twelfth night /
por: Shakespeare, William, 1564-1616
Publicado: (1975)

Twelfth Meeting
por: Blewett, Myrtle Hildred
Publicado: (1970)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The Renaissance of the twelfth century.
por: Haskins, Charles Homer, 1870-1937
Publicado: (1957)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
por: Ma, Lichun, et al.
Publicado: (2015)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2014)

Twelfth rib syndrome: a case report
por: Jung, Jaewoong, et al.
Publicado: (2020)

Twelfth night, or, What you will
por: Shakespeare, William, 1564-1616
Publicado: (1994)

Twelfth night of wat you will /
por: Shakespeare, William, 1564-1616
Publicado: (1982)

Twelfth International Medical Congress
Publicado: (1896)

Mortality Statistics in the Twelfth Census
Publicado: (1899)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2021)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
por: L’Hostis, Adèle, et al.
Publicado: (2023)

Solitary osteochondroma of the twelfth rib with intraspinal extension and cord compression in a middle-aged patient
por: Shim, Jung Hyun, et al.
Publicado: (2012)

Twelfth International Conference on Grey Literature
por: Farace, D J
Publicado: (2010)

Twelfth George H. Hudson Symposium
por: Fleury, Patrick J
Publicado: (1982)

Twelfth degree spline with application to quadrature
por: Mohammed, P. O., et al.
Publicado: (2016)

Maimonides, a Twelfth Century Physician
por: Mendelson, Walter
Publicado: (1923)

The Rise of Medicine at Salerno in the Twelfth Century
por: Corner, George W.
Publicado: (1931)

Circular—Mortality Statistics in the Twelfth Census
por: Merriam, William R.
Publicado: (1899)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
por: Wang, Yue-qin, et al.
Publicado: (2020)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
por: Liu, Ning, et al.
Publicado: (2020)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
por: Greulich, Heidi, et al.
Publicado: (2005)

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
por: Xu, Chuncao, et al.
Publicado: (2021)

Review of the twelfth West Coast retrovirus meeting
por: Barry, Sheila M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_un2jfnrfqfohegu87cte31g4um